menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Lupin gets USFDA nod for generic HIV drug

    ECONOMICTIMES

    Lupin receives FDA tentative approval for HIV treatment generic

    EXPRESSPHARMA

    ViiV To Present Dovato Vs Biktarvy Trial Data At AIDS 2024

    INDIANPHARMAPOST

    ViiV Healthcare To Present Dovato Vs Biktarvy Trial Data At AIDS 2024

    BUSINESSWIRE

    ViiV Healthcare announces FDA Approval of Dovato for Adolescents Living with HIV

    BUSINESSWIRE

    ViiV Health announces new packaging option now available in the U.S. for Dovato

    BUSINESSWIRE

    Colombia to seek compulsory license on ViiV`s dolutegravir

    FIERCE PHARMA

    GSK`s ViiV to lean on HIV portfolio ahead of dolutegravir patent expiration

    ENDPTS

    Viatris Announces U.S. FDA Approval of a Paediatric Formulation of Abacavir

    PR NEWSWIRE

    ViiV Healthcare`s Dovato (dolutegravir, lamivudine) Receives Approval in Europe

    EMA

    Lupin gets FDA tentative approval for dolutegravir tablets for oral suspension

    PHARMABIZ

    Lupin`s Generic Dolutegravir Sodium Receives Approval in the U.S.

    FDA

    FDA Confirms Paragraph IV Patent Litigation for Abacavir Sulfate, Dolutegravir and Lamivudine Tablets

    FDA

    Lupin gets USFDA nod for Dolutegravir, Emtricitabine and Tenofovir tablets

    ECONOMIC TIMES

    Lupin`s Generic Dolutegravir Sodium, Emtricitabine and Tenofovir Alafenamide Receives Approval in the U.S.

    FDA

    Lupin`s Generic Dolutegravir Sodium and Rilpivirine Receives Approval in the U.S.

    FDA

    ViiV Healthcare`s Dovato (dolutegravir / lamivudine) Receives Approval in the Europe

    EMA

    Diabetes, patented TB, HIV drugs enter essential list

    ECONOMICTIMES

    Exavir to publish PC data for ultra-long-acting dolutegravir prodrug XVIR-120

    GLOBENEWSWIRE

    FDA Approves ViiV’s Triumeq PD for Children With HIV

    BLOOMBERG LAW

    ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV

    PRESS RELEASE

    GSK announces $1.25 bln settlement between ViiV Healthcare, Gilead

    REUTERS

    ViiV seeks FDA approval for dispersible single tablet regimen with dolutegravir

    PHARMABIZ

    ViiV seeks FDA approval for dispersible single tablet regimen with dolutegravir

    PHARMABIZ

    ViiV submits FDA application for dispersible single tablet regimen dolutegravir

    PRESS RELEASE

    ViiV Healthcare presents three-year switch data for Dovato

    BUSINESSWIRE

    Shionogi licenses out 3rd-gen HIV asset to ViiV

    FIERCEBIOTECH

    PrEP updates and new products at IAS 2021

    WHO

    Virologic, Clinical Failure Rates Low With Dolutegravir: Presented at IAS

    FIRSTWORDPHARMA

    HIV generic drug for babies distributed in Africa, says UNITAID

    REUTERS

    Takeda launches rare disease diagnosis programme for patients

    PHARMABIZ

    The Food and Drug Administration approved revisions to the TRIUMEQ

    FDA

    Pfizer COVID-19 vaccine set to generate sales of $30 billion

    EUROPEANPHARMACEUTICALREVIEW

    EU approval for ViiV’s Tivicay for children living with HIV

    PHARMATIMES

    ViiV receives EU Marketing Authorisation for the first-ever dolutegravir

    PRESS RELEASE

    ViiV gets EU approval for children`s HIV treatment

    PHARMAFILE

    ViiV gets EU approval for children`s HIV treatment

    PHARMAFILE

    Viatris Announces FDA Tentative Approval of a Pediatric Dolutegravir (DTG)

    PRNEWSWIRE

    Study suggests dolutegravir is the optimal first-line HIV medication

    EUROPEANPHARMACEUTICALS

    Dolutegravir plus lamivudine shows non-inferior HIV-1 in Ph III trials

    EUROPEALPHARMACEUTICAL

    Hetero Labs Unit`s Generic Dolutegravir Receives Tentative Approval In US

    FDA

    ViiV reports promising data from Phase IIIb HIV study of Dovato

    CLINICALTRIALSARENA

    Sun’s dolutegravir 50mg tablet prequalified

    WHO

    ViiV Healthcare announces FDA approval of an expanded indication for Dovato

    BUSINESSWIRE

    US approves first dispersible tablet formulation of Tivicay

    PHARMATIMES

    FDA approves ViiV Healthcare’s Tivicay to treat HIV in children

    PHARMACEUTICAL

    U.S. FDA approves GSK unit`s drug to treat infants and children with HIV

    REUTERS

    GSK ViiV`s Dovato triumphs in #FierceMadness DTC ad contest

    FIERCEPHARMA

    Dolutegravir and the possible risk of neural tube defects

    MED SAFE

    GSK`s plan to take over the HIV drug market hasn`t worked out

    BIOPHARMADIVE

    Roche`s Ocrevus, GSK`s Dovato ads top November TV spending chart

    FIERCE PHARMA

    GSK`s ViiV launches first campaign for new HIV med Dovato

    FIERCE PHARMA

    20-year GSK veteran takes up CSO role at HemoShear

    FIERCE BIOTECH

    FDA Confirms Paragraph IV Patent Challenge of Dovato 211994 (Dolutegravir Sodium and Lamivudine)Tablets 50 mg/300 mg"

    FDA

    Top GSK/ViiV scientist who co-invented an HIV blockbuster books to biotech

    ENDPTS

    Aspen`s drug to prevent preterm birth approved by FDA

    ECONOMICTIMES

    Micro Labs Generic Dolutegravir Sodium Receives Tentative Approval in US

    FDA

    ViiV builds confidence in 2-drug HIV pill with new Dovato data

    FIERCE PHARMA

    ViiV’s Investigational HIV Drug Finds Success in Hard-to-Treat Patient

    BIOSPACE

    Fosun Pharma picks up GSK plant along with rights to make Epivir generic

    FIERCE PHARMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.